Alloy Therapeutics Raises $40M in Series E Funding

The round saw backers, including 8VC, JIC Venture Growth Investments, Echo Capital, and multiple family offices, who joined Alloy’s existing investors, Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, and Ulysses Diversified Holdings. The company is valued at $1 Billion valuation.

The company plans to use the funds to support growth in three key areas, improving its core discovery services in antibodies, genetic medicines, and cell therapies, expanding its preclinical and clinical development capabilities; and advancing its AI and data platform.

Alloy has worked with more than 200 partners across antibody, bispecific, genetic medicine, and cell therapy areas, resulting in over 100 licensed drug programs. Of these, 22 have entered clinical development, including 2 in Phase 3. Building on its drug discovery work, Alloy has expanded into the full development process, including pharmacology, preclinical and clinical services, and biologics manufacturing.

The future of drug development is shifting toward smaller, efficient teams that need high-quality tools without owning them. Alloy provides this by combining AI, real world data and lab services into one platform, offering on demand support while keeping partner data secure at every step.

The company is growing its presence with centers of excellence in the U.S., Japan, the Middle East, and other emerging markets. This supports its distributed model for the next phase of decentralized drug development.

Read More:Neato Raises $25M in Growth Capital Led by Advantage Capital

“Alloy is building the infrastructure that connects drug discovery, development, and data across the global biopharma industry,” said Errik Anderson, Founder and CEO of Alloy Therapeutics. He said the company is combining strengths from traditional pharma and modern tech-driven biotech to improve how new medicines are developed. He also noted that rapid advances in technology, including AI, are moving too quickly for any single pharma company to keep up with, so Alloy’s collaborative model helps partners stay current without having to build everything themselves.

“We’ve seen Errik carefully build Alloy over the past decade into a company that is reshaping drug development at scale,” said Alex Kolicich of 8VC. He added that while AI is disrupting many industries, real change in biopharma will come from combining AI with real-world lab and development work in a ‘human-in-the-loop’ style approach.

“Strengthening Japan’s role in global life sciences means investing in infrastructure that helps innovation move faster and more efficiently across borders,” said Hanae Suzuki of JIC Venture Growth Investments. She said Alloy’s model connects advanced technologies and services across different countries, including Japan, helping the country become more integrated into the global innovation ecosystem and supporting the development of globally competitive talent.

About Alloy

Founded in 2017 by Errik Anderson, Alloy Therapeutics is a biotech company that supports drug discovery and development using AI platforms and scientific expertise. It works through partnerships to give companies access to the tools, technologies, and services needed to develop new treatments, including antibodies, bispecifics, genetic medicines, cell therapies, and drug-delivery systems.

Read More:Turion Space Raises $75M+ in Series B Funding